Whilst pleased with revenue growth, the EBIT loss has still ballooned. I fear even if sales doubled, MVP still wouldn’t be profitable.
France withdrawal is a shock. This was supposed to be the key market for Europe, so what does that now mean for previous ambitions? Unattainable?
They have churned through most of the August 2022 capital raise in 12 months. The trade payables is much higher than trade receivables so the cash position as of today would be much lower than $20m.
Not starting US clinical work until FY25. Will this ever get done?
Selfie - why has this taken so long?
Whilst pleased with revenue growth, the EBIT loss has still...
Add MVP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
40.5¢ |
Change
-0.035(7.95%) |
Mkt cap ! $34.95M | |||
| Open | High | Low | Value | Volume |
| 44.0¢ | 45.0¢ | 40.5¢ | $82.07K | 192.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 6002 | 40.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 43.5¢ | 3044 | 1 |
View Market Depth
| Last trade - 16.10pm 07/06/2024 (20 minute delay) ? |
|
|||||
|
Last
40.5¢ |
Change
-0.035 ( 3.69 %) |
||||
| Open | High | Low | Volume | ||
| 42.5¢ | 43.5¢ | 40.5¢ | 43358 | ||
| Last updated 15.59pm 07/06/2024 ? | |||||
| MVP (ASX) Chart |